BMS re-applied for suspension about Eliquis

The MOHW releases suspension according to court decision, ₩1185 → ₩830 from the 1st

BMS re-applied suspension of appeal & price cut, ↑ Interested in Seoul High Court's decision

Eliquis' price has dropped by 30% since last 1st.

 

This is in accordance with the Seoul Administrative Court's decision at the end of last year.

 

However, It is also likely that drug prices will rise again in the 2nd course of legal disputes.

 

The Ministry of Health and Welfare recently announced that Eliquis' suspension of price cuts has been lifted as of January 1 through a notice of the ‘Pharmaceutical Benefit List and Reimbursement Limit Table’.

 

Eliquis’ price has been reduced from ₩1,185 to ₩830.

 

The action is in response to a decision made by the Seoul Administrative Court on December 19 last year.

 

The administrative court went for the defendant, welfare department in a minimum lawsuit for the adjustment of the upper limit on the amount of drug adjustments filed by BMS against the minister.

 

It was ruling that Eliquis' disposal of the drug price was justified following the launch of the generic..

 

Eliquis' price was initially to be reduced to July 1.

 

However, BMS has filed a series of petitions for suspension of drug price reduction and a minimum lawsuit.

 

The court accepted the BMS' claim.

 

The decision was made to suspend the price cut.

 

The Ministry of Health and Welfare delayed the Eliquis’ price cut twice.

 

The suspension lasted until December 31 of last year.

 

The court ruled in favor of the Ministry of Welfare, leaving approximately two weeks before the suspension of the Ministry of Welfare.

 

The suspension was lifted.

 

The price was automatically lowered from January 1 Eliquis' price may rise again.

 

This is because BMS who lost the first trial appealed to the Seoul High Court.

 

Indeed, BMS, the legal representative of BMS, was confirmed that the Ministry of Health and Welfare applied for suspension from the Seoul High Law immediately the day after the Ministry of Health and Welfare announced the suspension of drug price reduction.

 

The application for suspension shall be decided by the court, independent of a trial on an appeal case(Original suit).

 

The decision of the original case and the decision to suspend execution were allotted to the ninth administration of the Seoul High Court.

 

It is unknown whether the court will accept the BMS’ application.

 

The relevant trial date has not been set yet.

 

In general, most courts cite the application for suspension of drug price reduction, but it is difficult to predict easily that there is also the opposite case.

 

In the first trial, part 14 of the Seoul Administrative Court accepted the application for suspension of BMS.

 

On the contrary, in last September, part 6 of Seoul Administrative Court rejected the application for price reduction’s suspension of the disposable eye drops from 21 domestic pharmaceutical companies.